Literature DB >> 26539671

Pennsylvania comprehensive stroke center collaborative: Statement on the recently updated IV rt-PA prescriber information for acute ischemic stroke.

Badih Daou1, Maureen Deprince2, Robin D'Ambrosio2, Stavropoula Tjoumakaris1, Robert H Rosenwasser1, Daniel J Ackerman3, Rodney Bell3, Diana L Tzeng3, Michelle Ghobrial3, Andres Fernandez3, Qaisar Shah4, Dan J Gzesh5, Deborah Murphy4, John E Castaldo6, Claranne Mathiesen6, Maria Carissa Pineda3, Pascal Jabbour7.   

Abstract

OBJECTIVE: Recently, the FDA guidelines regarding the eligibility of patients with acute ischemic stroke to receive IV rt-PA have been modified and are not in complete accord with the latest AHA/ASA guidelines. The resultant differences may result in discrepancies in patient selection for intravenous thrombolysis.
METHODS: Several comprehensive stroke centers in the state of Pennsylvania have undertaken a collaborative effort to clarify and unify our own recommendations regarding how to reconcile these different guidelines.
RESULTS: Seizure at onset of stroke, small previous strokes that are subacute or chronic, multilobar infarct involving more than one third of the middle cerebral artery territory on CT scan, hypoglycemia, minor or rapidly improving symptoms should not be considered as contraindications for intravenous thrombolysis. It is recommended to follow the AHA/ASA guidelines regarding blood pressure management and bleeding diathesis. Patients receiving factor Xa inhibitors and direct thrombin inhibitors within the preceding 48 h should be excluded from receiving IV rt-PA. CT angiography is effective in identifying candidates for endovascular therapy. Consultation with and/or transfer to a comprehensive stroke center should be an option where indicated. Patients should receive IV rt-PA up to 4.5h after the onset of stroke.
CONCLUSIONS: The process of identifying patients who will benefit the most from IV rt-PA is still evolving. Considering the rapidity with which patients need to be evaluated and treated, it remains imperative that systems of care adopt protocols to quickly gather the necessary data and have access to expert consultation as necessary to facilitate best practices.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute ischemic stroke; IV rt-PA; Thrombolysis

Mesh:

Substances:

Year:  2015        PMID: 26539671     DOI: 10.1016/j.clineuro.2015.10.010

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  1 in total

1.  The positive effects of Xueshuan Xinmai tablets on brain functional connectivity in acute ischemic stroke: a placebo controlled randomized trial.

Authors:  Dongfeng Wei; Daojun Xie; He Li; Yaojing Chen; Di Qi; Yujiao Wang; Yangjun Zhang; Kewei Chen; Chuanfu Li; Zhanjun Zhang
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.